Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 16 Dec 2023
Reviewer's report:
Overall, there are many instances of non-standard punctuation in this draft.
The title of the study was too broad, favoring inflammatory colon disease over inflammatory
bowel disease.
There is no mention of the inclusion of "smoking habits" as a differentiator in the trial design,
but this is addressed in the subsequent study tables and in the discussion of the conclusions.
In the INTRODUCTION section, the role of IL-17 is described first, followed by a description
of the applications of IL-17, which is more in line with the reading order.
The METHODOLOGY section, in general, was a bit confusing and it felt like it was randomly
thrown together when you couldn't see the key sections.
There is no mention of how the situation "Patients may be "active" or "inactive” Patients may
be newly diagnosed or on existing therapy. " was handled in the categorized patient groups.
What is the rationale for the selection of the previous coefficients from “Sample size calculation
was based on correlation co-efficient…. ” , I hope that is reflected.
In the method presentation of serum IL-17 section, there is inconsistency in the formatting and
inconsistency in the detailed description of the ELISA method is something that needs to be
brought to one's attention, please show it. And there are more formatting errors in part " then
measured as mcg/g;( under 50 is considered to be normal., between 50 and 100, coupled with
digestive symptoms as IBS , between 100 and 250 is inconclusive, and over 250 means IBD
is likely."
In the colonoscopy section, there are expressions of unclear meaning like " After staining with
haematoxylin and eosin."
The RESULTS section is simply a stack of tables, the labeling of the tables is sloppy, table 1
does not indicate the meaning of KW, and a short summary of the results of the charts would be
appreciated. The curves in Figure 1 are also not clearly labeled.
Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 16 Dec 2023
Reviewer's report:
Overall, there are many instances of non-standard punctuation in this draft.
The title of the study was too broad, favoring inflammatory colon disease over inflammatory
bowel disease.
There is no mention of the inclusion of "smoking habits" as a differentiator in the trial design,
but this is addressed in the subsequent study tables and in the discussion of the conclusions.
In the INTRODUCTION section, the role of IL-17 is described first, followed by a description
of the applications of IL-17, which is more in line with the reading order.
The METHODOLOGY section, in general, was a bit confusing and it felt like it was randomly
thrown together when you couldn't see the key sections.
There is no mention of how the situation "Patients may be "active" or "inactive” Patients may
be newly diagnosed or on existing therapy. " was handled in the categorized patient groups.
What is the rationale for the selection of the previous coefficients from “Sample size calculation
was based on correlation co-efficient…. ” , I hope that is reflected.
In the method presentation of serum IL-17 section, there is inconsistency in the formatting and
inconsistency in the detailed description of the ELISA method is something that needs to be
brought to one's attention, please show it. And there are more formatting errors in part " then
measured as mcg/g;( under 50 is considered to be normal., between 50 and 100, coupled with
digestive symptoms as IBS , between 100 and 250 is inconclusive, and over 250 means IBD
is likely."
In the colonoscopy section, there are expressions of unclear meaning like " After staining with
haematoxylin and eosin."
The RESULTS section is simply a stack of tables, the labeling of the tables is sloppy, table 1
does not indicate the meaning of KW, and a short summary of the results of the charts would be
appreciated. The curves in Figure 1 are also not clearly labeled.
Please review this paper.
user
Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 16 Dec 2023
Reviewer's report:
Overall, there are many instances of non-standard punctuation in this draft.
The title of the study was too broad, favoring inflammatory colon disease over inflammatory
bowel disease.
There is no mention of the inclusion of "smoking habits" as a differentiator in the trial design,
but this is addressed in the subsequent study tables and in the discussion of the conclusions.
In the INTRODUCTION section, the role of IL-17 is described first, followed by a description
of the applications of IL-17, which is more in line with the reading order.
The METHODOLOGY section, in general, was a bit confusing and it felt like it was randomly
thrown together when you couldn't see the key sections.
There is no mention of how the situation "Patients may be "active" or "inactive” Patients may
be newly diagnosed or on existing therapy. " was handled in the categorized patient groups.
What is the rationale for the selection of the previous coefficients from “Sample size calculation
was based on correlation co-efficient…. ” , I hope that is reflected.
In the method presentation of serum IL-17 section, there is inconsistency in the formatting and
inconsistency in the detailed description of the ELISA method is something that needs to be
brought to one's attention, please show it. And there are more formatting errors in part " then
measured as mcg/g;( under 50 is considered to be normal., between 50 and 100, coupled with
digestive symptoms as IBS , between 100 and 250 is inconclusive, and over 250 means IBD
is likely."
In the colonoscopy section, there are expressions of unclear meaning like " After staining with
haematoxylin and eosin."
The RESULTS section is simply a stack of tables, the labeling of the tables is sloppy, table 1
does not indicate the meaning of KW, and a short summary of the results of the charts would be
appreciated. The curves in Figure 1 are also not clearly labeled.
assistant